Treatment of stable chronic bronchitis with iodinated glycerol: a double-blind, placebo-controlled trial.
In a double-blind trial, 29 patients were treated for stable, chronic bronchitis with iodinated glycerol (Organidin, 60 mg four times daily; n = 16) or placebo (n = 13). The study consisted of a 2-week single-blind lead-in period, followed by a 6-week double-blind treatment period, and assessed a total of 50 response variables. In this set of patients, treatment with iodinated glycerol was associated with statistically significant (P < 0.05) and/or positive trend (P < 0.1) toward improvement in cough frequency, cough severity, difficulty in raising sputum, sputum thickness, sputum stickiness, forced expiratory flow at FVC25%-75%, cell concentration in sputum, and several measures of physician assessment of patient condition. Iodinated glycerol was well tolerated during the 6-week treatment period; no adverse effects were reported and no patient receiving iodinated glycerol withdrew from the study prematurely. In conclusion, this study demonstrates that iodinated glycerol, 60-mg tablets given in a total daily dose of 240 mg, is safe and effective therapy for reducing symptoms in patients with stable, chronic bronchitis.
Repsher
L H
LH
Occupational and Environmental Lung Disease Program, Lutheran Medical Center, Wheat Ridge, Colorado.
D000328:Adult; D001991:Bronchitis / Q000188:drug therapy* / Q000473:pathology; D002908:Chronic Disease; D003371:Cough / Q000473:pathology; D004311:Double-Blind Method; D005100:Expectorants / Q000627:therapeutic use*; D005260:Female; D005990:Glycerol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008450:Maximal Midexpiratory Flow Rate; D013183:Sputum / Q000187:drug effects / Q000378:metabolism
D005100:Expectorants; C015372:iodinated glycerol; D005990:Glycerol